H.u.group Holdings, Inc. · TSE:4544

H.u.group — Q3 FY2023 Earnings Presentation

20 slides from H.u.group's earnings presentation, Feb 9, 2024

  1. Slide 1: Financial Results for The Third Quarter of FY2023

    Financial Results for The Third Quarter of FY2023 (Ended Dec. 31, 2023) February 9, 2024 （TSE: 4544）

  2. Slide 2: Notes & references

    Notes & references: * The financial information in this document follows Japanese GAAP, with the exception for EBITDA (Operating profit + Depreciation + Amortization of goodwill), which is a non-GAAP measure. * In some cases, “Net Profit attributable to shareholders of the parent company” may be abb

  3. Slide 3: Financial Results for The Third Quarter of FY2023

    Financial Results for The Third Quarter of FY2023 2

  4. Slide 4: Consolidated Results for 9 Months FY2023

    Consolidated Results for 9 Months FY2023 (\ billion) 9 Months FY2022 9 Months FY2023 Profit Profit Variance Results Results ratio ratio Net sales 201.0 177.5 -23.45 -11.7% LTS 124.7 110.0 -14.75 -11.8% IVD 55.6 46.4 -9.19 -16.5% HS 20.6 21.1 +0.48 +2.3% 1 Operating profit/loss 23.7 11.8% -1.1 -0.6%

  5. Slide 5: Consolidated Net Sales Changes

    Consolidated Net Sales Changes (\ billion) 220 201.0 -14.75 200 -9.19 1 180 38.7 +0.48 177.5 1 Decrease in COVID-19 tests: -74% 10.1 160 162.3 Growth in base business: +3% 167.4 140 0 9 Months LTS IVD HS 9 Months FY22 FY23 4 1. Net sales related to COVID-19 testing

  6. Slide 6: Consolidated Operating Profit Changes

    Consolidated Operating Profit Changes (\ billion) (＋) Efficiency effect of profitability improvement (－) Profit decrease due to decrease in COVID-19-related tests 25 23.7 -11.22 (－) Marginal profit decrease due to increase in raw material costs, etc. 20 (－) Profit decrease due to decrease in Covid-1

  7. Slide 7: Consolidated Ordinary Profit/Loss & Net Profit/Loss

    Consolidated Ordinary Profit/Loss & Net Profit/Loss Ordinary Profit/Loss Net Profit/Loss (\ billion) (\ billion) 25 23.2 25 18.8 20 20 15 15 10 10 5 5 -2.9 -3.3 0 0 -5 9 Months 9 Months -5 9 Months 9 Months FY22 FY23 FY22 FY23 Major non-operating factors  Foreign exchange gains \0.41 B  Equity in

  8. Slide 8: Quarterly Performance Trend

    Quarterly Performance Trend Net sales EBITDA, OP (\ billion) Net sales related to (\ billion) Net sales EBITDA Operating Profit 90 COVID-19 testing 45 75.1 70.2 68.8 66.9 62.5 61.9 63.5 64.1 65.3 59.9 59.9 61.0 60 54.7 18.7 23.2 15.0 11.4 56.6 30 9.5 12.9 11.8 12.3 6.4 4.0 3.2 12.2 2.9 43.9 6.2 55.5

  9. Slide 9: LTS

    LTS Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 60 18 9 Months 9 Months Variance FY22 FY23 Net sales 124.7 110.0 -14.75 -11.8% Off-site 95.7 88.5 -7.28 -7.6% 39.7 38.4 37.7 40 36.1 36.2 12 FMS/Branch 24.1 18.4 -5.66 -23.5% 2.0 2.1 1.3 Others 4.9 3.1 -1.8

  10. Slide 10: IVD

    IVD Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 24 20 9 Months 9 Months Variance 20.4 FY22 FY23 Net sales 55.6 46.4 -9.19 -16.5% Lumipulse 28.1 19.6 -8.46 -30.1% 4.0 16.9 16.2 Japan 25.2 17.1 -8.13 -32.2% 14.4 2.7 Overseas 2.9 2.5 -0.33 -11.5% 6.2 13.4 3

  11. Slide 11: HS Quarterly Results YoY Comparison

    HS Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 10 4 9 Months 9 Months Variance FY22 FY23 Net sales 20.6 21.1 +0.48 +2.3% 6.8 7.1 7.2 6.9 7.1 Sterilization 16.0 16.4 +0.46 +2.9% Home-visiting, 1.6 1.6 1.6 4.7 4.7 +0.02 +0.4% 1.6 1.6 welfare EBITDA 2.06 10

  12. Slide 12: Cash, Deposits and Interest-bearing Debts

    Cash, Deposits and Interest-bearing Debts (\ billion) FY2023 FY2022 Cash and deposits Short-term debts 44.2 40.4 46.5 Interest- Long-term debts Cash and 30.5 bearing debts deposits Lease debts Corporate Interest- 3.7 3.6 6.7 bond bearing debts 29.0 18.7 15.0 Net interest-bearing 25.0 -26.5 debt bala

  13. Slide 13: Analysis of Consolidated Cash Flows (9 Months FY2023)

    Analysis of Consolidated Cash Flows (9 Months FY2023) Investment cash (\ billion) Operating cash flows +9.4 Others -9.2 flows -9.2 Free cash flows +0.2 1 1 -33.0 -9.0 (Increase in net interest-bearing debts） -42.0 March 31, 2023 December 31, 2023 Operating capital: -3.0 Increase in Refund of Operati

  14. Slide 14: Analysis of Consolidated Cash Flows (9 Months FY2022)

    Analysis of Consolidated Cash Flows (9 Months FY2022) Investment cash (\ billion) Operating cash flows +19.3 Others -7.7 flows -24.9 Free cash flows -5.6 1 1 -26.5 -13.3 (Increase in net interest-bearing debts） -39.8 March 31, 2022 Decrease in December 31, 2022 purchase debts 2 Depreciation +3.4 -0.

  15. Slide 15: Forecast of FY2023

    Forecast of FY2023 FES y.u.croup

  16. Slide 16: FY2023 Full-year Forecast

    FY2023 Full-year Forecast (\ billion) The Full-year Forecast remains consistent with November 2023 announcement FY2023 FY2023 FY2022 Full-year vs 9 Months FY2023 Q4 results target previous year results forecast Net sales 260.9 240.0 -20.9 -8.0% 177.5 62.5 EBITDA 43.1 25.0 -18.1 -42.0% 14.3 10.7 OP 2

  17. Slide 17: 9 Months Results and Q4 Forecasts ①

    9 Months Results and Q4 Forecasts ① Despite variations in individual factors, the full-year forecast for operating income is expected to reach 4.0 billion yen 9 Months results Q4 forecasts Details ※ 120 Monthly hospital requisition Index 病院における月次受付件数Index （2022年度＝100） (Base volume: FY2022=100) 1 110

  18. Slide 18: 9 Months Results and Q4 Forecasts ②

    9 Months Results and Q4 Forecasts ② 9 months results Q4 forecasts Details The count of COVID-19 cases 2023年5月8日週（第19週）以降の 新型コロナウイルス感染症定点当たり報告数 since May 8th, 2023 1 ※ • Peaked out as COVID-19- expected Demand for COVID- related 19-related testing • The inflection rate testing began rising again coul

  19. Slide 19: AkirunoCube Costs and Effects

    AkirunoCube Costs and Effects • Delaying full operations led to higher one-time costs and some delay in realizing the full-year forecasted effects set at the beginning of the fiscal year • Depreciation and running costs are expected to be lower than the initial full-year assumption Full-year FY23 9

  20. Slide 20: Contact information

    【Contact information】 IR/SR Department Email : ir@hugp.com Disclaimer regarding forward-looking statement: The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncerta

H.U. Group Holdings — Q3 FY2023 Earnings Presentation on 6ix